The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.01 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -1.18 — flag raised, worth a closer lookWatch
- Earnings quality 52/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Arcturus Therapeutics Holdings Inc. reports it. History and quarterly detail are in the app.
- Collaboration Revenue$67.2M
- Grant$14.8M
Leadership changes
From Arcturus Therapeutics Holdings Inc.'s own filings, the day they're filed.
- Joe Roberts · appointmenteff. 2025-12-12
- Joseph Roberts · appointmenteff. 2024-03-15
- Moncef Slaoui · appointment
Latest filings
- 8-K · Company announcement2026-06-05
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
- DEF 14A · Annual proxy (pay & governance)2026-04-24
- 10-K · Annual report2026-03-03
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Arcturus Therapeutics Holdings Inc., every answer cited🔒
- The Intelligence Brief — added when Arcturus Therapeutics Holdings Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.